TR199701096T1 - Tienil-, Furil-, Pirolil- ve Bifenils�lfonamidler ve Bunlar�n Endotelin Etkinli�ini D�zenleyen T�revleri. - Google Patents

Tienil-, Furil-, Pirolil- ve Bifenils�lfonamidler ve Bunlar�n Endotelin Etkinli�ini D�zenleyen T�revleri.

Info

Publication number
TR199701096T1
TR199701096T1 TR97/01096T TR9701096T TR199701096T1 TR 199701096 T1 TR199701096 T1 TR 199701096T1 TR 97/01096 T TR97/01096 T TR 97/01096T TR 9701096 T TR9701096 T TR 9701096T TR 199701096 T1 TR199701096 T1 TR 199701096T1
Authority
TR
Turkey
Prior art keywords
zenleyen
revleri
pyrrolil
lfonamidler
etkinli
Prior art date
Application number
TR97/01096T
Other languages
English (en)
Turkish (tr)
Inventor
Fai Chan Ming
Gowda Raju Bore
Kois Adam
Joel Verner Erik
Wu Chengde
Silverstre Castillo Rosario
Yalamoori Venkatachalapathi
Narayanaiyengar Balaji Vitukudi
Kogan Timothy
Original Assignee
Texas Biotechnology Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27411089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199701096(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/477,223 external-priority patent/US5594021A/en
Application filed by Texas Biotechnology Corporation filed Critical Texas Biotechnology Corporation
Publication of TR199701096T1 publication Critical patent/TR199701096T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
TR97/01096T 1995-04-04 1996-04-04 Tienil-, Furil-, Pirolil- ve Bifenils�lfonamidler ve Bunlar�n Endotelin Etkinli�ini D�zenleyen T�revleri. TR199701096T1 (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41619995A 1995-04-04 1995-04-04
US41707595A 1995-04-04 1995-04-04
US08/477,223 US5594021A (en) 1993-05-20 1995-06-06 Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin

Publications (1)

Publication Number Publication Date
TR199701096T1 true TR199701096T1 (xx) 1998-02-21

Family

ID=27411089

Family Applications (1)

Application Number Title Priority Date Filing Date
TR97/01096T TR199701096T1 (xx) 1995-04-04 1996-04-04 Tienil-, Furil-, Pirolil- ve Bifenils�lfonamidler ve Bunlar�n Endotelin Etkinli�ini D�zenleyen T�revleri.

Country Status (24)

Country Link
EP (2) EP1048657A1 (enExample)
JP (3) JP3233642B2 (enExample)
KR (2) KR100359396B1 (enExample)
CN (1) CN1130355C (enExample)
AT (1) ATE243203T1 (enExample)
AU (1) AU711968B2 (enExample)
CA (1) CA2217169C (enExample)
CZ (1) CZ299246B6 (enExample)
DE (2) DE122006000068I1 (enExample)
DK (1) DK0819125T3 (enExample)
EA (2) EA007107B1 (enExample)
EE (1) EE9700251A (enExample)
ES (1) ES2201181T3 (enExample)
FI (1) FI973879A0 (enExample)
HU (1) HUP9802034A3 (enExample)
NL (1) NL300251I2 (enExample)
NO (1) NO315607B1 (enExample)
NZ (2) NZ306734A (enExample)
OA (1) OA10621A (enExample)
PL (1) PL186854B1 (enExample)
PT (1) PT819125E (enExample)
TR (1) TR199701096T1 (enExample)
TW (1) TW492966B (enExample)
WO (1) WO1996031492A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
WO1997029747A1 (en) 1996-02-20 1997-08-21 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
NZ336898A (en) * 1997-04-28 2001-10-26 Texas Biotechnology Corp Sulfonamides for treatment of endothelin-mediated disorders
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
GB9803228D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
CN1149196C (zh) * 1998-07-06 2004-05-12 布里斯托尔-迈尔斯斯奎布公司 作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺
DE69928260T2 (de) * 1998-07-08 2006-07-20 Sanofi-Aventis Deutschland Gmbh Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
ATE482930T1 (de) 1999-08-06 2010-10-15 Takeda Pharmaceutical Substituierte aromatische ringverbindungen, verfahren zu ihrer herstellung und ihre anwendung
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
CN1414965A (zh) * 1999-12-31 2003-04-30 德州生物科技公司 调整内皮肽活性的磺酰胺及其衍生物
WO2001049289A1 (en) * 1999-12-31 2001-07-12 Texas Biotechnology Corporation Pharmaceutical and veterinary uses of endothelin antagonists
EP1533311B1 (en) * 1999-12-31 2007-04-25 Encysive Pharmaceuticals, Inc Sulfonamides and derivatives thereof that modulate the activity of endothelin
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
US7071220B2 (en) 2000-09-18 2006-07-04 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
JP3847711B2 (ja) * 2000-09-18 2006-11-22 トーアエイヨー株式会社 Ｎ置換ベンゾチオフェンスルホンアミド誘導体
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US20030152956A1 (en) * 2000-12-26 2003-08-14 Noriko Ohtani Method of examining allergic disease
DE60333351D1 (de) * 2002-03-15 2010-08-26 Toa Eiyo Ltd N-substituiertes benzothiophensulfonamidderivat
AU2003261415C1 (en) 2002-08-09 2010-01-14 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
WO2004014300A2 (en) 2002-08-09 2004-02-19 Merck & Co., Inc. Tyrosine kinase inhibitors
SE0301882D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use I
SE0301886D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use V
SE0301883D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use II
SE0301884D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use III
SE0301885D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use IV
SE0301888D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use VII
KR101325519B1 (ko) * 2004-10-14 2013-11-08 애보트 게엠베하 운트 콤파니 카게 도파민 ｄ3 수용체의 조절에 반응하는 장애를 치료하기에적합한 아릴설포닐메틸 또는 아릴설폰아미드 치환된 방향족화합물
CN101730694A (zh) 2007-04-10 2010-06-09 奥斯拜客斯制药有限公司 用于治疗高血压的取代的氘富集的噻吩
CA2963784A1 (en) 2007-06-08 2008-12-18 Mannkind Corporation Ire-1.alpha. inhibitors
US8592470B2 (en) * 2012-01-31 2013-11-26 Eisai R&D Management Co., Ltd. Sitaxentan derivative
CN107652246B (zh) * 2017-09-25 2020-08-25 江苏乾元生物科技有限公司 一种3-[3-溴-2-甲基-6-(甲基磺酰基)苯基]-4,5-二氢化异噁唑的制备方法
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
AU2020296361A1 (en) 2019-06-18 2022-01-06 Ctxt Pty Ltd Benzisoxazole sulfonamide derivatives
EP3831940A1 (en) * 2019-12-05 2021-06-09 Danmarks Tekniske Universitet Small molecule inhibitors of crispr-cas associated activity
CN112663077B (zh) * 2021-01-11 2022-07-01 陕西师范大学 一种苯并磺内酰胺类化合物的电化学制备方法
AU2022297082B2 (en) 2021-06-22 2024-04-18 Alchemedicine, Inc. Compound, endothelin A receptor antagonist and pharmaceutical composition
JP2024523576A (ja) 2021-07-09 2024-06-28 ヴィコール ファルマ アーベー 新規の選択的アンジオテンシンｉｉ化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660383A (en) * 1968-08-14 1972-05-02 Shionogi & Co Production of iodoisoxazole compounds
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
TW224462B (enExample) * 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
IL116916A (en) * 1995-02-06 2000-09-28 Bristol Myers Squibb Co Substituted biphenyl sulfonamide derivatives and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
EE9700251A (et) 1998-04-15
JP3527217B2 (ja) 2004-05-17
TW492966B (en) 2002-07-01
NZ500282A (en) 2000-01-28
JP2004043495A (ja) 2004-02-12
NO974577D0 (no) 1997-10-03
NL300251I2 (nl) 2007-03-01
EA199700208A1 (ru) 1998-08-27
CA2217169A1 (en) 1996-10-10
OA10621A (en) 2001-03-16
HK1001769A1 (en) 1998-07-10
NL300251I1 (nl) 2007-02-01
NZ306734A (enExample) 2000-01-28
CA2217169C (en) 2005-03-29
WO1996031492A1 (en) 1996-10-10
DE69628740D1 (de) 2003-07-24
ATE243203T1 (de) 2003-07-15
PL186854B1 (pl) 2004-03-31
KR19980703679A (ko) 1998-12-05
DK0819125T3 (da) 2003-10-13
EA199900808A1 (ru) 2000-06-26
HUP9802034A3 (en) 2000-04-28
CN1184470A (zh) 1998-06-10
EP1048657A1 (en) 2000-11-02
NO974577L (no) 1997-12-04
FI973879A0 (fi) 1997-10-03
PT819125E (pt) 2003-11-28
KR100359396B1 (ko) 2003-03-15
EA007107B1 (ru) 2006-06-30
AU711968B2 (en) 1999-10-28
ES2201181T3 (es) 2004-03-16
CZ311697A3 (cs) 1998-09-16
HUP9802034A2 (hu) 2000-03-28
PL322707A1 (en) 1998-02-16
CN1130355C (zh) 2003-12-10
EP0819125A1 (en) 1998-01-21
EP0819125B1 (en) 2003-06-18
JP3233642B2 (ja) 2001-11-26
CZ299246B6 (cs) 2008-05-28
AU5536796A (en) 1996-10-23
NO315607B1 (no) 2003-09-29
DE122006000068I1 (de) 2007-05-10
JP2002030075A (ja) 2002-01-29
DE69628740T2 (de) 2004-05-13
KR100359397B1 (ko) 2002-11-01
JPH11507015A (ja) 1999-06-22

Similar Documents

Publication Publication Date Title
TR199701096T1 (xx) Tienil-, Furil-, Pirolil- ve Bifenils�lfonamidler ve Bunlar�n Endotelin Etkinli�ini D�zenleyen T�revleri.
TR199900705T2 (xx) Endotelin etkinli�ini d�zenleyen s�lfonamidler ve t�revleri.
EE200200363A (et) Sulfoonamiidid ja nende derivaadid, mis moduleerivad endoteliini aktiivsust
TR200100874T2 (tr) Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi
ATE399177T1 (de) Derivate therapeutischer peptide
TR200202738T2 (tr) Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler
BR0317872A (pt) Medicamentos antiinflamatórios
DE69922822D1 (de) Rekombinante haarbehandlungsmittel
ATE245977T1 (de) Therapeutische substituierte guanidine
BG96323A (bg) Нов полипептид и анти-нiv лекарство,получено от него
PT896615E (pt) Peptido proveniente de uma forma soluvel de acetilcolinesterase activo como modulador dos canais de calcio
ATE218857T1 (de) Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen
ATE48759T1 (de) Behandlung von anfaellen und hierfuer nuetzliche pharmazeutische zusammensetzungen.
ATE3416T1 (de) Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
Baizhanov One-types in weakly o-minimal theories
ATE158947T1 (de) Hautregenerierende kosmetische zusammensetzung
ITRM920506A1 (it) Regioni antigeniche dei complessi tpl e anticorpi diretti contro di essi.
TR199902866T2 (xx) Organo- koruyucu aktiviteye sahip yeni BPC peptid tuzlar�, haz�rlanmalar� ve terapide kullan�lmalar� i�in prosesler.
DE69619530D1 (de) Zyklische somatostatinanaloge mit wachstumhormon inhibierender aktivität
FR2720938B1 (fr) Composition dermato-cosmétologique et son utilisation.
CA2288439A1 (en) Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
KR950007870A (ko) 암 전이 억제제 및 동물용 암 전이 억제제
KR960037048A (ko) 우르솔린산을 함유하는 콜라게나제 발현 저해제